Epigenetic modifiers: activities in renal cell carcinoma.

Nature Reviews. Urology
Aguirre A de Cubas, W Kimryn Rathmell

Abstract

Renal cell carcinomas (RCCs) are a diverse set of malignancies that have recently been shown to harbour mutations in a number of chromatin modifier genes - including PBRM1, SETD2, BAP1, KDM5C, KDM6A, and MLL2 - through high-throughput sequencing efforts. Current research focuses on understanding the biological activities that chromatin modifiers employ to suppress tumorigenesis and on developing clinical approaches that take advantage of this knowledge. Unsurprisingly, several common themes unify the functions of these epigenetic modifiers, particularly regulation of histone post-translational modifications and nucleosome organization. Furthermore, chromatin modifiers also govern processes crucial for DNA repair and maintenance of genomic integrity as well as the regulation of splicing and other key processes. Many chromatin modifiers have additional non-canonical roles in cytoskeletal regulation, which further contribute to genomic stability, expanding the repertoire of functions that might be essential in tumorigenesis. Our understanding of how mutations in chromatin modifiers contribute to tumorigenesis in RCC is improving but remains an area of intense investigation. Importantly, elucidating the activities of chromatin modi...Continue Reading

References

Nov 26, 1996·Proceedings of the National Academy of Sciences of the United States of America·S AcharyaR Fishel
Aug 11, 1997·Gene·S J ClarkP L Molloy
Dec 31, 1997·Medicine·E R Maher, W G Kaelin
Jan 19, 2000·Nature·B D Strahl, C D Allis
Jun 8, 2001·Annual Review of Biochemistry·C M Pickart
Feb 13, 2002·Molecular and Cellular Biology·Brian D StrahlC David Allis
Sep 6, 2002·Biochimica Et Biophysica Acta·Michael S Kobor, Jack Greenblatt
May 4, 2004·Molecular and Cellular Biology·Kairong CuiKeji Zhao
Jun 2, 2004·The Biochemical Journal·Xiaomei WangElizabeth Moran
Jun 10, 2004·British Journal of Cancer·S BamfordR Wooster
Sep 24, 2004·Nature·Hengbin WangYi Zhang
Dec 9, 2004·Proceedings of the National Academy of Sciences of the United States of America·Amy E PalmerRoger Y Tsien
Dec 17, 2004·Genes & Development·Zhong WangRobert Tjian
Jun 15, 2005·Annual Review of Biochemistry·Mary Grace Goll, Timothy H Bestor
Sep 17, 2005·Molecular and Cellular Biology·Satish SankaranJeffrey D Parvin
Nov 30, 2005·Proceedings of the National Academy of Sciences of the United States of America·Ming LiPei Zhou
Feb 14, 2006·Science·Michael Shogren-KnaakCraig L Peterson
Aug 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gennady BratslavskyW Marston Linehan
Sep 6, 2007·Cell Cycle·Kristen J Verhey, Jacek Gaertig
Jan 31, 2008·British Journal of Cancer·N Bucher, C D Britten
Sep 24, 2008·The Journal of Biological Chemistry·Matthias D KaeserBeverly M Emerson
Oct 17, 2008·Nature Reviews. Cancer·William G Kaelin
Dec 9, 2008·Trends in Biochemical Sciences·Ronald C Conaway, Joan Weliky Conaway
Dec 23, 2008·The Journal of Biological Chemistry·Niall S KennethSonia Rocha
Feb 3, 2009·Nature Genetics·Paulina Kolasinska-ZwierzJulie Ahringer
Feb 24, 2009·Oncogene·D ReismanE A Thompson
Apr 10, 2009·Annual Review of Biochemistry·Cedric R Clapier, Bradley R Cairns
May 16, 2009·Current Cancer Drug Targets·I R H M KoningsS Sleijfer
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel Y C HengToni K Choueiri
Feb 6, 2010·Proceedings of the National Academy of Sciences of the United States of America·Ming HuZhu Chen
Mar 25, 2010·Journal of Cell Science·Tomohiro HayakawaPaul R Andreassen
May 4, 2010·Nature·Johanna C ScheuermannJürg Müller
Oct 15, 2010·The New England Journal of Medicine·Kimberly C WiegandDavid G Huntsman

❮ Previous
Next ❯

Citations

Jan 11, 2019·International Journal of Cancer. Journal International Du Cancer·Wolfgang A SchulzAnnemarie Greife
Apr 18, 2019·Molecular & Cellular Proteomics : MCP·Pengsheng ChenHaiteng Deng
Mar 4, 2020·Oncogene·Melissa M WolfKathryn E Beckermann
Jul 24, 2020·The Journal of Clinical Investigation·Jenny C LinkKaren Reue
Sep 29, 2019·International Journal of Molecular Sciences·Wolfgang A Schulz, Karina D Sørensen
May 30, 2020·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Hsiang-Chih LuJennifer K Sehn
Jul 28, 2020·Genes·Diego Ingrosso, Alessandra F Perna
Sep 19, 2020·The Cancer Journal·Roy EliasJames Brugarolas
Aug 18, 2020·Radiation Oncology·Kexu XiangJohann Matschke
Oct 4, 2020·Science Advances·Riyad N H SeervaiCheryl Lyn Walker
May 31, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James J HardingJohanna C Bendell
Dec 8, 2020·Frontiers in Oncology·Chunyue FengJianhua Mao
Jul 1, 2019·Molecular & Cellular Proteomics : MCP·Pengsheng ChenHaiteng Deng
Nov 5, 2020·Nature Reviews. Nephrology·Eric JonaschW Kimryn Rathmell
Oct 11, 2020·Biochemical and Biophysical Research Communications·Riyad N H SeervaiCheryl Lyn Walker
Jun 24, 2021·Asia-Pacific Journal of Clinical Oncology·Xin TongTaoping Shi
Apr 8, 2020·Experimental and Molecular Pathology·Paranita FerronikaKlaas Kok
Aug 26, 2021·European Journal of Haematology·Aaron M GoodmanRazelle Kurzrock

❮ Previous
Next ❯

Methods Mentioned

BETA
PBAF
glycosylation
sites
xenograft
X-ray
acetylation
immunoprecipitation

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.